World Biotech API Market Potential Examined in New Topical Study Now Available at MarketPublishers.com20 Jun 2012 • by Natalie Aster
LONDON – The global API market has been advancing at a significant growth rate in recent times and it is likely to register a healthy CAGR of around 8% during 2012-2015, supported by factors such as emergence of India and China as prominent API manufacturing hub, patent expiration of blockbuster drugs and technological innovation to drive HPAPI segment, as well as impressive participation of private players.
Biotech APIs have a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical industry and gaining applications of biotech drugs, biotech API’s are sure to see a highly prospective market in the future. The branded APIs currently dominate the biotech APIs market; however, with growing patent expiries and advancements in the market structure, the generic APIs will see a rapid growth.
New market research study “Global Biotech API Market Analysis” elaborated by RNCOS E-Services has been recently published by Market Publishers Ltd.
Global Biotech API Market Analysis
Published: June, 2012
Price: US$ 1.000,00
The study presents unbiased analysis and forecast for the biotech API market from a global perspective. It analyses the regulatory structure in the API and the biotech API market covering the mandates and guidelines for manufacturing, safety, and good manufacturing practices (GMP). The report also provides elaborate profiles the top companies involved in the biotech API business to gain insights on their overall business, biotech API functioning, recent activities, along with analysis of their strengths and weaknesses. Furthermore, prudent market segmentation and forecasts; the geographic analysis and regulatory overview can also be found in the review.
Companies discussed include: Bayer Pharma AG, Bayer Pharma AG, Boehringer Ingelheim, Hospira, Lonza, Ranbaxy Laboratories, Royal Dsm N.V., Sigma-Aldrich, Teva Active Pharmaceutical Ingredients, Zhejiang Hisun Pharmaceutical Co. Ltd.
More new market research reports by the publisher can be found at RNCOS E-Services page.